SMARCA4 loss disrupts DNA repair via defective homologous recombination (HR) and mismatch repair (MMR), increasing tumor mutation burden (TMB) by 10–15 mutations/Mb compared to SMARCA4-intact sarcomas (22, 23). This evidence concerns the gene SMARCA4 and neoplasm.